Concourse Financial Group Securities, Inc. Indaptus Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$1.13 - $2.25 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.0 - $2.8 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.63 - $2.8 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.75 - $2.75 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.75 - $3.95 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.75 - $3.95 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.6 - $3.04 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.51 - $1.9 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.37 - $2.19 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.16 - $3.33 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.94 - $4.02 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.19 - $6.17 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.21 - $7.93 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$7.07 - $14.84 $0 - $0

Others Institutions Holding INDP

# of Institutions

Shares Held

605K

Call Options Held

Put Options Held

View Full List

About Indaptus Therapeutics, Inc.

Ticker INDP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,258,600
Market Cap $8.51M
Description
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...

More about INDP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account